TY -的T1 -减少谷氨酸+谷氨酰胺在阿尔茨海默病检测体内1 <一口> < /一口> H-MRS 0.5 T JF -神经学乔-神经病学SP - 737 LP - 742 - 10.1212 / WNL.56.6.737六世- 56 - 6非盟-首页皮耶罗g . Antuono AU -珍妮弗·l·琼斯李盟-少年王盟Shi-Jiang Y1 - 2001/03/27 UR - //www.ez-admanager.com/content/56/6/737.abstract N2 -目的:确定谷氨酸+谷氨酰胺(GLX)水平在大脑中测量体内质子夫人在0.5特斯拉(T)区分可能阿尔茨海默氏症和正常老化。背景:Glutamatergic标记测量之前在死亡的脑组织。传统的质子在1.5 T夫人不能可靠地检测GLX共振体内。作者开发了一种技术在0.5 T敏感GLX共振。方法:使用肌酸和磷酸肌酸代谢物比率共振作为内部标准获得的扣带地区18 AD患者和健康对照组12。主要的共振光谱检查:N-acetylaspartate (NAA) choline-containing化合物,肌醇,GLX。细微精神状态检查(MMSE)是用来评估认知状态。工具性日常生活活动量表(工具性ADL)被用来评估功能状态。结果:减少的比率GLX (−10%, p = 0.001)和NAA (−12%, p = 0.000)患者被发现广告。AD患者的比率增加肌醇走近意义(+ 14%)。 GLX ratios of patients with AD were correlated with MMSE (r = 0.61, p = 0.007) and Instrumental ADL (r = 0.59, p = 0.01) scores. The combined sensitivity of NAA and myo-inositol in correctly diagnosing AD was 78%. The addition of GLX to NAA and myo-inositol increased the sensitivity to 89%. Overall diagnostic accuracy improved from 80 to 83% with the addition of GLX. Conclusions: Glutamate + glutamine reduction may be a biologic marker for AD and may be a potential aid in the early clinical diagnosis of AD. ER -